NeuroBo Pharmaceuticals Files 8-K

Ticker: MTVA · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1638287

Neurobo Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyNeurobo Pharmaceuticals, INC. (MTVA)
Form Type8-K
Filed DateOct 7, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

NeuroBo filed an 8-K, standard procedure, no major news.

AI Summary

NeuroBo Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates NeuroBo Pharmaceuticals is providing standard disclosures and financial updates to the SEC, which is routine for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by NeuroBo Pharmaceuticals?

The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as of October 7, 2024.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is October 7, 2024.

In which state is NeuroBo Pharmaceuticals, Inc. incorporated?

NeuroBo Pharmaceuticals, Inc. is incorporated in Delaware.

What is the address of NeuroBo Pharmaceuticals' principal executive offices?

The address is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.

What was NeuroBo Pharmaceuticals' former company name?

NeuroBo Pharmaceuticals' former company name was Gemphire Therapeutics Inc.

Filing Stats: 673 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-10-07 07:00:29

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure . On October 7, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation to its website at https://www.neurobopharma.com/events-presentations/presentations , which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). Information contained on or accessible through any website reference in the corporate presentation is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the corporate presentation is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate Presentation dated October 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: October 7, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing